GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...
A semi-annual analysis of the Chinese CPAP market highlights fluctuations that reflect regulatory changes, product launches, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback